Fibrinogen

Inflammatory

Acute-Phase Markers

Fibrinogen is a clotting protein made by the liver that also behaves as an acute-phase reactant, rising when the body is inflamed. Beyond its role in forming clots, elevated fibrinogen independently predicts cardiovascular events, which is why a preventive practice tracks it as both a clotting and an inflammation marker.

What It Measures

Clotting factor and acute-phase protein; elevated fibrinogen independently predicts cardiovascular events

Optimal vs. Lab Range

Longevity Optimal

200–300 mg/dL

Target range for optimal health and longevity based on research.

Standard Lab

200–400 mg/dL

Population-based reference range from standard labs.

Why It Matters

High fibrinogen raises blood viscosity and clotting tendency while also reflecting active inflammation, a combination that maps onto higher cardiovascular and stroke risk. Because it independently predicts cardiovascular events, it can flag risk that a standard lipid panel misses. Elevations are commonly linked to inflammation, infection, tissue injury, and smoking, so the value often points toward a modifiable driver. In a longevity framework, keeping fibrinogen in a favorable range supports vascular health and reduces the clot-related component of cardiovascular aging. Very low levels are uncommon and may instead signal liver disease or a clotting disorder.

When Low

Liver disease (can't produce fibrinogen), DIC, afibrinogenemia

When High

Cardiovascular risk, stroke risk, inflammation, infection, tissue injury, smoking

How to Optimize

Smoking cessation is one of the most direct ways to lower an elevated fibrinogen, since tobacco is a common driver. Regular aerobic exercise and adequate omega-3 intake from fatty fish or supplementation can support healthier levels over time. Nattokinase is sometimes considered as an adjunct and is best discussed with your physician. Because fibrinogen tracks inflammation, addressing any underlying inflammatory condition also helps bring it down. Targets and treatment are individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Strong evidence

Key Interventions

Omega-3

nattokinase

exercise

smoking cessation

Linked Compounds & Supplements

Omega-3

Nattokinase

Lumbrokinase

Vitamin E

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum or plasma (venous draw)

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Semi-annual

Reporting unit

Confirm with the performing lab — units vary by region.

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Fibrinogen.
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.